Philip Low has received several national and international research awards, an NIH Merit Award, and both of Purdue University’s awards for outstanding research. He has published over 270 refereed articles and currently serves on 4 editorial boards and several external advisory boards for major institutions.
Philip’s research into receptor-targeted therapeutic and imaging agents has lead to more than 30 U.S. patents/patents pending. Thus far, the development of these patents has yielded 5 targeted drugs that are currently undergoing human clinical trials for kidney, ovarian, breast, lung, brain and endometrial cancers. He has founded a company called Endocyte Inc. based on this technology.
Philip has been a member of Purdue University faculty since 1976 and is currently the Ralph C. Corley Distinguished Professor of Chemistry.